Global Systemic Psoriasis Therapeutic Market

Systemic Psoriasis Therapeutic Comprehensive Study by Type (Plaque Psoriasis, Psoriatic Arthritis, Others), Route of Administration (Oral, Parenteral/Systemic, Topical), Distribution Channel (Direct, Indirect), Treatment Type (Biological, Non-Biological), Drug Class (TNF Inhibitors, Interleukins Inhibitors, Others) Players and Region - Global Market Outlook to 2027

Systemic Psoriasis Therapeutic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Systemic Psoriasis Therapeutic Market Scope
Psoriasis is a common chronic autoimmune inflammatory skin disease that affects 2 to 3% of the global population. Thickened, erythematous, scaly plaques that are often pruritic are typical symptoms of the disease. Psoriasis typically appears in early adulthood (between the ages of 15 and 25 years), but it can strike at any age. Psoriasis progresses through chronic and acute phases, with varying relapse and remission rates. Furthermore, psoriasis is frequently associated with other comorbidities such as psoriatic arthritis, obesity, inflammatory bowel disease, diabetes, and cardiovascular disease. Chronic plaque psoriasis is the most common clinical psoriasis phenotype, accounting for all but 10% of cases. Systemic treatment with biological agents, nonbiologic agents, and phototherapy are all options for more widespread diseases. Nonbiologic systemic therapies may be effective, but they can have serious short- and long-term side effects (hepatotoxicity, nephrotoxicity, hypertension, dyslipidemia, malignancy, and teratogenicity). Although considered one of the safer therapeutic options, phototherapy requires strict adherence, and the long-term toxicity associated with it includes photocarcinogenesis.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAbbVie Inc. (United States), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (United States), Pfizer Inc. (United States), LEO Pharma A/S (Denmark), Merck & Co., Inc. (United States), Amgen Inc. (United States), Eli Lilly and Company (United States), Evelo Biosciences, Inc. (United States) and UCB S.A. (Belgium)
CAGR%


To entice more end users, market players are focusing on providing Systematic psoriasis therapeutics with higher quality while adhering to all regulatory standards. In the global Systematic psoriasis therapeutics market, there are numerous large and small-scale service providers. They are also concentrating on the implementation of numerous advanced technologies in the development of better scents. Furthermore, the numerous industry profits have led to the entry of new players, raising the level of rivalry in an already competitive market. The Systematic psoriasis therapeutics market is currently expanding due to the rapid advancement of the pharmaceutical industry and increase in investment in R&D. Some of the key players in this market follow strategies, which include new product offerings, and products approvals, partnerships and alliances, mergers, and acquisitions, and business expansions. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Systemic Psoriasis Therapeutic market throughout the predicted period.

AbbVie Inc. (United States), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (United States), Pfizer Inc. (United States), LEO Pharma A/S (Denmark), Merck & Co., Inc. (United States), Amgen Inc. (United States), Eli Lilly and Company (United States), Evelo Biosciences, Inc. (United States) and UCB S.A. (Belgium) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Sun Pharmaceutical Industries Ltd. (India).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Systemic Psoriasis Therapeutic market by Type and Region with country level break-up.

On the basis of geography, the market of Systemic Psoriasis Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2021.

Market Leaders and their expansionary development strategies
In May 2020, AbbVie, a research-based global biopharmaceutical company, announced today that it has completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and approval by the Irish High Court.
In January 2022 AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.
The American Academy of Dermatology has issued treatment guidelines for psoriasis. As previously stated, topical agents, as well as targeted phototherapy, are effective treatments for the limited disease. There are no clear guidelines for selecting first-line therapy when treating patients with more extensive disease, despite the fact that the presence of concomitant psoriatic arthritis is an important determinant of treatment choice (often a TNF-alpha inhibitor with or without methotrexate). Guidelines recommend either biologic or nonbiologic systemic agents or phototherapy with ultraviolet B (UVB) or psoralen plus ultraviolet A (PUVA) therapy for patients with widespread disease. There are few direct comparative trials comparing effectiveness within or between biologic and nonbiologic classes.

Systemic Psoriasis Therapeutic Market Dynamics:
AttributesDetails
Trends Influencing Market
  • Rising Advancement in Biotechnology and Drugs.
Key Restraints
  • The Drugs Used in this Treatment can Cause Side Effects.
Challenges
  • The Rising Mutation of Disease.
Market Opportunities
  • The Effectiveness of Current Treatments Hints at the Possibility of a Cure Further Down the Line.


Key Target Audience
Pharmaceutical companies, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Others
By Route of Administration
  • Oral
  • Parenteral/Systemic
  • Topical

By Distribution Channel
  • Direct
  • Indirect

By Treatment Type
  • Biological
  • Non-Biological

By Drug Class
  • TNF Inhibitors
  • Interleukins Inhibitors
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Psoriasis Being a Genetic or Linked to Other Diseases Effect Approx. 125 Million People Every Year. Making it Necessary for Having Better Treatments.
    • 3.3. Market Challenges
      • 3.3.1. The Rising Mutation of Disease.
    • 3.4. Market Trends
      • 3.4.1. Rising Advancement in Biotechnology and Drugs.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Systemic Psoriasis Therapeutic, by Type, Route of Administration, Distribution Channel, Treatment Type, Drug Class and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Systemic Psoriasis Therapeutic (Value)
      • 5.2.1. Global Systemic Psoriasis Therapeutic by: Type (Value)
        • 5.2.1.1. Plaque Psoriasis
        • 5.2.1.2. Psoriatic Arthritis
        • 5.2.1.3. Others
      • 5.2.2. Global Systemic Psoriasis Therapeutic by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral/Systemic
        • 5.2.2.3. Topical
      • 5.2.3. Global Systemic Psoriasis Therapeutic by: Distribution Channel (Value)
        • 5.2.3.1. Direct
        • 5.2.3.2. Indirect
      • 5.2.4. Global Systemic Psoriasis Therapeutic by: Treatment Type (Value)
        • 5.2.4.1. Biological
        • 5.2.4.2. Non-Biological
      • 5.2.5. Global Systemic Psoriasis Therapeutic by: Drug Class (Value)
        • 5.2.5.1. TNF Inhibitors
        • 5.2.5.2. Interleukins Inhibitors
        • 5.2.5.3. Others
      • 5.2.6. Global Systemic Psoriasis Therapeutic Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Systemic Psoriasis Therapeutic (Price)
      • 5.3.1. Global Systemic Psoriasis Therapeutic by: Type (Price)
  • 6. Systemic Psoriasis Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. LEO Pharma A/S (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amgen Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Evelo Biosciences, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. UCB S.A. (Belgium)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Systemic Psoriasis Therapeutic Sale, by Type, Route of Administration, Distribution Channel, Treatment Type, Drug Class and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Systemic Psoriasis Therapeutic (Value)
      • 7.2.1. Global Systemic Psoriasis Therapeutic by: Type (Value)
        • 7.2.1.1. Plaque Psoriasis
        • 7.2.1.2. Psoriatic Arthritis
        • 7.2.1.3. Others
      • 7.2.2. Global Systemic Psoriasis Therapeutic by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral/Systemic
        • 7.2.2.3. Topical
      • 7.2.3. Global Systemic Psoriasis Therapeutic by: Distribution Channel (Value)
        • 7.2.3.1. Direct
        • 7.2.3.2. Indirect
      • 7.2.4. Global Systemic Psoriasis Therapeutic by: Treatment Type (Value)
        • 7.2.4.1. Biological
        • 7.2.4.2. Non-Biological
      • 7.2.5. Global Systemic Psoriasis Therapeutic by: Drug Class (Value)
        • 7.2.5.1. TNF Inhibitors
        • 7.2.5.2. Interleukins Inhibitors
        • 7.2.5.3. Others
      • 7.2.6. Global Systemic Psoriasis Therapeutic Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Systemic Psoriasis Therapeutic (Price)
      • 7.3.1. Global Systemic Psoriasis Therapeutic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Systemic Psoriasis Therapeutic: by Type(USD Million)
  • Table 2. Systemic Psoriasis Therapeutic Plaque Psoriasis , by Region USD Million (2016-2021)
  • Table 3. Systemic Psoriasis Therapeutic Psoriatic Arthritis , by Region USD Million (2016-2021)
  • Table 4. Systemic Psoriasis Therapeutic Others , by Region USD Million (2016-2021)
  • Table 5. Systemic Psoriasis Therapeutic: by Route of Administration(USD Million)
  • Table 6. Systemic Psoriasis Therapeutic Oral , by Region USD Million (2016-2021)
  • Table 7. Systemic Psoriasis Therapeutic Parenteral/Systemic , by Region USD Million (2016-2021)
  • Table 8. Systemic Psoriasis Therapeutic Topical , by Region USD Million (2016-2021)
  • Table 9. Systemic Psoriasis Therapeutic: by Distribution Channel(USD Million)
  • Table 10. Systemic Psoriasis Therapeutic Direct , by Region USD Million (2016-2021)
  • Table 11. Systemic Psoriasis Therapeutic Indirect , by Region USD Million (2016-2021)
  • Table 12. Systemic Psoriasis Therapeutic: by Treatment Type(USD Million)
  • Table 13. Systemic Psoriasis Therapeutic Biological , by Region USD Million (2016-2021)
  • Table 14. Systemic Psoriasis Therapeutic Non-Biological , by Region USD Million (2016-2021)
  • Table 15. Systemic Psoriasis Therapeutic: by Drug Class(USD Million)
  • Table 16. Systemic Psoriasis Therapeutic TNF Inhibitors , by Region USD Million (2016-2021)
  • Table 17. Systemic Psoriasis Therapeutic Interleukins Inhibitors , by Region USD Million (2016-2021)
  • Table 18. Systemic Psoriasis Therapeutic Others , by Region USD Million (2016-2021)
  • Table 19. South America Systemic Psoriasis Therapeutic, by Country USD Million (2016-2021)
  • Table 20. South America Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 21. South America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 22. South America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 23. South America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 24. South America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 25. Brazil Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 26. Brazil Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 27. Brazil Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 28. Brazil Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 29. Brazil Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 30. Argentina Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 31. Argentina Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 32. Argentina Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 33. Argentina Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 34. Argentina Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 35. Rest of South America Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 36. Rest of South America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 37. Rest of South America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 38. Rest of South America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 39. Rest of South America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 40. Asia Pacific Systemic Psoriasis Therapeutic, by Country USD Million (2016-2021)
  • Table 41. Asia Pacific Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 42. Asia Pacific Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 43. Asia Pacific Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 44. Asia Pacific Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 45. Asia Pacific Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 46. China Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 47. China Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 48. China Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 49. China Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 50. China Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 51. Japan Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 52. Japan Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 53. Japan Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 54. Japan Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 55. Japan Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 56. India Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 57. India Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 58. India Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 59. India Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 60. India Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 61. South Korea Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 62. South Korea Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 63. South Korea Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 64. South Korea Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 65. South Korea Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 66. Taiwan Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 67. Taiwan Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 68. Taiwan Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 69. Taiwan Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 70. Taiwan Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 71. Australia Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 72. Australia Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 73. Australia Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 74. Australia Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 75. Australia Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 76. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 77. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 78. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 79. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 80. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 81. Europe Systemic Psoriasis Therapeutic, by Country USD Million (2016-2021)
  • Table 82. Europe Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 83. Europe Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 84. Europe Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 85. Europe Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 86. Europe Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 87. Germany Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 88. Germany Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 89. Germany Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 90. Germany Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 91. Germany Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 92. France Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 93. France Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 94. France Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 95. France Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 96. France Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 97. Italy Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 98. Italy Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 99. Italy Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 100. Italy Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 101. Italy Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 102. United Kingdom Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 103. United Kingdom Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 104. United Kingdom Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 105. United Kingdom Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 106. United Kingdom Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 107. Netherlands Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 108. Netherlands Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 109. Netherlands Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 110. Netherlands Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 111. Netherlands Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 112. Rest of Europe Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 113. Rest of Europe Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 114. Rest of Europe Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 115. Rest of Europe Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 116. Rest of Europe Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 117. MEA Systemic Psoriasis Therapeutic, by Country USD Million (2016-2021)
  • Table 118. MEA Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 119. MEA Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 120. MEA Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 121. MEA Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 122. MEA Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 123. Middle East Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 124. Middle East Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 125. Middle East Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 126. Middle East Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 127. Middle East Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 128. Africa Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 129. Africa Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 130. Africa Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 131. Africa Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 132. Africa Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 133. North America Systemic Psoriasis Therapeutic, by Country USD Million (2016-2021)
  • Table 134. North America Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 135. North America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 136. North America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 137. North America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 138. North America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 139. United States Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 140. United States Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 141. United States Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 142. United States Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 143. United States Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 144. Canada Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 145. Canada Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 146. Canada Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 147. Canada Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 148. Canada Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 149. Mexico Systemic Psoriasis Therapeutic, by Type USD Million (2016-2021)
  • Table 150. Mexico Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2016-2021)
  • Table 151. Mexico Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2016-2021)
  • Table 152. Mexico Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2016-2021)
  • Table 153. Mexico Systemic Psoriasis Therapeutic, by Drug Class USD Million (2016-2021)
  • Table 154. Systemic Psoriasis Therapeutic: by Type(USD/Units)
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Systemic Psoriasis Therapeutic: by Type(USD Million)
  • Table 166. Systemic Psoriasis Therapeutic Plaque Psoriasis , by Region USD Million (2022-2027)
  • Table 167. Systemic Psoriasis Therapeutic Psoriatic Arthritis , by Region USD Million (2022-2027)
  • Table 168. Systemic Psoriasis Therapeutic Others , by Region USD Million (2022-2027)
  • Table 169. Systemic Psoriasis Therapeutic: by Route of Administration(USD Million)
  • Table 170. Systemic Psoriasis Therapeutic Oral , by Region USD Million (2022-2027)
  • Table 171. Systemic Psoriasis Therapeutic Parenteral/Systemic , by Region USD Million (2022-2027)
  • Table 172. Systemic Psoriasis Therapeutic Topical , by Region USD Million (2022-2027)
  • Table 173. Systemic Psoriasis Therapeutic: by Distribution Channel(USD Million)
  • Table 174. Systemic Psoriasis Therapeutic Direct , by Region USD Million (2022-2027)
  • Table 175. Systemic Psoriasis Therapeutic Indirect , by Region USD Million (2022-2027)
  • Table 176. Systemic Psoriasis Therapeutic: by Treatment Type(USD Million)
  • Table 177. Systemic Psoriasis Therapeutic Biological , by Region USD Million (2022-2027)
  • Table 178. Systemic Psoriasis Therapeutic Non-Biological , by Region USD Million (2022-2027)
  • Table 179. Systemic Psoriasis Therapeutic: by Drug Class(USD Million)
  • Table 180. Systemic Psoriasis Therapeutic TNF Inhibitors , by Region USD Million (2022-2027)
  • Table 181. Systemic Psoriasis Therapeutic Interleukins Inhibitors , by Region USD Million (2022-2027)
  • Table 182. Systemic Psoriasis Therapeutic Others , by Region USD Million (2022-2027)
  • Table 183. South America Systemic Psoriasis Therapeutic, by Country USD Million (2022-2027)
  • Table 184. South America Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 185. South America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 186. South America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 187. South America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 188. South America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 189. Brazil Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 190. Brazil Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 191. Brazil Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 192. Brazil Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 193. Brazil Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 194. Argentina Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 195. Argentina Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 196. Argentina Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 197. Argentina Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 198. Argentina Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 199. Rest of South America Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 200. Rest of South America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 201. Rest of South America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 202. Rest of South America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 203. Rest of South America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 204. Asia Pacific Systemic Psoriasis Therapeutic, by Country USD Million (2022-2027)
  • Table 205. Asia Pacific Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 206. Asia Pacific Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 207. Asia Pacific Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 208. Asia Pacific Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 209. Asia Pacific Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 210. China Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 211. China Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 212. China Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 213. China Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 214. China Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 215. Japan Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 216. Japan Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 217. Japan Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 218. Japan Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 219. Japan Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 220. India Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 221. India Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 222. India Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 223. India Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 224. India Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 225. South Korea Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 226. South Korea Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 227. South Korea Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 228. South Korea Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 229. South Korea Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 230. Taiwan Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 231. Taiwan Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 232. Taiwan Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 233. Taiwan Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 234. Taiwan Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 235. Australia Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 236. Australia Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 237. Australia Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 238. Australia Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 239. Australia Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 240. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 241. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 242. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 243. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 244. Rest of Asia-Pacific Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 245. Europe Systemic Psoriasis Therapeutic, by Country USD Million (2022-2027)
  • Table 246. Europe Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 247. Europe Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 248. Europe Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 249. Europe Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 250. Europe Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 251. Germany Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 252. Germany Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 253. Germany Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 254. Germany Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 255. Germany Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 256. France Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 257. France Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 258. France Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 259. France Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 260. France Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 261. Italy Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 262. Italy Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 263. Italy Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 264. Italy Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 265. Italy Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 266. United Kingdom Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 267. United Kingdom Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 268. United Kingdom Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 269. United Kingdom Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 270. United Kingdom Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 271. Netherlands Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 272. Netherlands Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 273. Netherlands Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 274. Netherlands Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 275. Netherlands Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 276. Rest of Europe Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 277. Rest of Europe Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 278. Rest of Europe Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 279. Rest of Europe Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 280. Rest of Europe Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 281. MEA Systemic Psoriasis Therapeutic, by Country USD Million (2022-2027)
  • Table 282. MEA Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 283. MEA Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 284. MEA Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 285. MEA Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 286. MEA Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 287. Middle East Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 288. Middle East Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 289. Middle East Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 290. Middle East Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 291. Middle East Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 292. Africa Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 293. Africa Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 294. Africa Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 295. Africa Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 296. Africa Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 297. North America Systemic Psoriasis Therapeutic, by Country USD Million (2022-2027)
  • Table 298. North America Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 299. North America Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 300. North America Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 301. North America Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 302. North America Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 303. United States Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 304. United States Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 305. United States Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 306. United States Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 307. United States Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 308. Canada Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 309. Canada Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 310. Canada Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 311. Canada Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 312. Canada Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 313. Mexico Systemic Psoriasis Therapeutic, by Type USD Million (2022-2027)
  • Table 314. Mexico Systemic Psoriasis Therapeutic, by Route of Administration USD Million (2022-2027)
  • Table 315. Mexico Systemic Psoriasis Therapeutic, by Distribution Channel USD Million (2022-2027)
  • Table 316. Mexico Systemic Psoriasis Therapeutic, by Treatment Type USD Million (2022-2027)
  • Table 317. Mexico Systemic Psoriasis Therapeutic, by Drug Class USD Million (2022-2027)
  • Table 318. Systemic Psoriasis Therapeutic: by Type(USD/Units)
  • Table 319. Research Programs/Design for This Report
  • Table 320. Key Data Information from Secondary Sources
  • Table 321. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Systemic Psoriasis Therapeutic: by Type USD Million (2016-2021)
  • Figure 5. Global Systemic Psoriasis Therapeutic: by Route of Administration USD Million (2016-2021)
  • Figure 6. Global Systemic Psoriasis Therapeutic: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Systemic Psoriasis Therapeutic: by Treatment Type USD Million (2016-2021)
  • Figure 8. Global Systemic Psoriasis Therapeutic: by Drug Class USD Million (2016-2021)
  • Figure 9. South America Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 10. Asia Pacific Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 11. Europe Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 12. MEA Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 13. North America Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 14. Global Systemic Psoriasis Therapeutic: by Type USD/Units (2016-2021)
  • Figure 15. Global Systemic Psoriasis Therapeutic share by Players 2021 (%)
  • Figure 16. Global Systemic Psoriasis Therapeutic share by Players (Top 3) 2021(%)
  • Figure 17. Global Systemic Psoriasis Therapeutic share by Players (Top 5) 2021(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie Inc. (United States) Revenue: by Geography 2021
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 23. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 27. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 28. LEO Pharma A/S (Denmark) Revenue: by Geography 2021
  • Figure 29. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co., Inc. (United States) Revenue: by Geography 2021
  • Figure 31. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Amgen Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 35. Evelo Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Evelo Biosciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 37. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 38. UCB S.A. (Belgium) Revenue: by Geography 2021
  • Figure 39. Global Systemic Psoriasis Therapeutic: by Type USD Million (2022-2027)
  • Figure 40. Global Systemic Psoriasis Therapeutic: by Route of Administration USD Million (2022-2027)
  • Figure 41. Global Systemic Psoriasis Therapeutic: by Distribution Channel USD Million (2022-2027)
  • Figure 42. Global Systemic Psoriasis Therapeutic: by Treatment Type USD Million (2022-2027)
  • Figure 43. Global Systemic Psoriasis Therapeutic: by Drug Class USD Million (2022-2027)
  • Figure 44. South America Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 45. Asia Pacific Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 46. Europe Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 47. MEA Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 48. North America Systemic Psoriasis Therapeutic Share (%), by Country
  • Figure 49. Global Systemic Psoriasis Therapeutic: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Novartis AG (Switzerland)
  • Johnson & Johnson Services, Inc. (United States)
  • Pfizer Inc. (United States)
  • LEO Pharma A/S (Denmark)
  • Merck & Co., Inc. (United States)
  • Amgen Inc. (United States)
  • Eli Lilly and Company (United States)
  • Evelo Biosciences, Inc. (United States)
  • UCB S.A. (Belgium)
Additional players considered in the study are as follows:
Sun Pharmaceutical Industries Ltd. (India)
Select User Access Type

Key Highlights of Report


Aug 2022 234 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Systemic Psoriasis Therapeutic Market Quantitative research analysis
Global Systemic Psoriasis Therapeutic Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Systemic Psoriasis Therapeutic Market are by type [Plaque Psoriasis, Psoriatic Arthritis and Others], by end use application [].
The Systemic Psoriasis Therapeutic Market is gaining popularity and expected to see strong valuation by 2027.
  • Psoriasis Being a Genetic or Linked to Other Diseases Effect Approx. 125 Million People Every Year. Making it Necessary for Having Better Treatments.

Know More About Global Systemic Psoriasis Therapeutic Market Report?

Have a Query? Click Here

Other Related Reports

Systemic Lupus Erythematosus Treatment Comprehensive Study by Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antimalarial Drugs, Corticosteroids, Immunosuppressants, Biologics, Others), End use...
$ 3800
Human Papillomavirus Therapeutics Comprehensive Study by Route of Administration (Parenteral, Topical), Vaccine Type (Peptide-based Vaccines, Protein-based Vaccines, Viral-vectored vaccines, Bacteria...
$ 3800
Neuropsychiatric Disorders And Treatment Comprehensive Study by Types (Degenerative Diseases, Psychosis, Neurotic Disorder), End Users (Hospitals, Specialty Clinics, Research & Development Centers, A...
$ 3800
Sepsis and Septic Shock Comprehensive Study by Type (Automated Diagnostics, Conventional Diagnostics), By End User (Hospitals, Pathology Center, Laboratories, Research Organization, Others), By Techn...
$ 3800
Upper-limb Robotic Neurorehabilitation Comprehensive Study by Type (Exoskeletons, End-effector Devices, Robotic Arms, Electrical Stimulation Devices, VR Systems, Others), By End User (Hospitals & Cli...
$ 3800
TMJ Disorders Comprehensive Study by Type (Muscular, Structural, Acute), Treatment (-Nonsurgical Treatments, Mouth Guards, Physical Therapy, Trigger Point Injections, Others, -Surgery, Arthrocentesis...
$ 3800